ArticleAllergy & rhinology (Providence, R.I.)2014
Novel treatment of allergic fungal sinusitis using omalizumab.
Article in Allergy & rhinology (Providence, R.I.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 23 citations in OpenAlex.
- Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis.The Laryngoscope · 2025Article
- Dupilumab: An emerging therapy in allergic fungal rhinosinusitis.The World Allergy Organization journal · 2022Article
- Invasive and Non-Invasive Fungal Rhinosinusitis-A Review and Update of the Evidence.Medicina (Kaunas, Lithuania) · 2019Review
- Allergic Aspergillus Rhinosinusitis.Journal of fungi (Basel, Switzerland) · 2016Review
- The Effectiveness of Dupilumab in Treating Pediatric Refractory Allergic Fungal Rhinosinusitis.Therapeutic advances in allergy and rhinologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A case report of recalcitrant allergic fungal sinusitis (AFS) refractory to systemic corticosteroids and multiple functional endoscopic sinus surgeries (FESSs) treated with anti-IgE antibody omalizumab is reported. AFS is often classified with chronic rhinosinusitis (CRS). Although similar symptoms are among the two diseases, AFS has a unique pathophysiology. Patients with AFS demonstrate type 1 hypersensitivity to fungal allergens, increased total serum IgE, increased CD8(+) T-cell prevalence, and IL-4 and IL-5 response. Omalizumab should be considered in the treatment of AFS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.